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Heterogeneity of antibodies in Goodpasture syndrome reacting with
type IV collagen. Sera from patients with antiglomerular basement
membrane (anti-GBM) antibodies associated with Goodpasture syn-
drome (GP) or glomerulonephritis were tested by ELISA and electroim-
munoblot against whole basement membrane collagen (type IV) iso-
lated from bovine anterior lens capsule (ALC) and bacterial collagenase
resistant domains of the collagen molecule, that is, the NC-I and 7-S
domains isolated from either ALC or bovine and human glomerular
basement membrane (GBM).1 Reactivity was high with the NC-I
domain by both the ELISA and the electroimmunoblot techniques.
Some of the anti-GBM sera reacted with both the NC-I and 7-S domains
of both human and bovine type IV collagen. At a time when the
patients' sera reacted weakly with a collagenase digest of human GBM
using a radioimmunoassay, the reactivity with the NC-I domain was
also low, but some of the sera continued to react with the 7-S domain.
The data suggest that there may be heterogeneity in the nature of
autoantibodies with respect to collagen type IV domain reactivity in the
sera of patients with anti-GBM antibody disease.
Anti-glomerular basement membrane (anti-GBM) antibody
production in humans causes glomerulonephritis. When this
condition is associated with episodic pulmonary hemorrhage it
is referred to as Goodpasture syndrome (GP) [1]. The antibod-
ies in these patients react with basement membranes in a
variety of tissues including glomerular basement membrane
(GBM), tubular and alveolar basement membranes, as well as
those of choroid plexus, intestine and lens capsule [1—31. Our
current knowledge of the degree of heterogeneity of these
autoantibodies and their respective epitopes is incomplete. A
radioimmunoassay developed some years ago by Wilson [4] has
been used routinely to detect anti-GBM antibodies that react
with an immunoaffinity purified fraction of collagenase-solubi-
lized human GBM [2]. In recent years a number of studies
[5—13] have demonstrated that sera from patients with anti-
GBM antibodies react with intact procollagen type IV mole-
cules of basement membranes, specifically with components of
the NC-i domain of type IV collagen from GBM and anterior
lens capsule (ALC). The immunoreactivity is directed at the
'Abbreviations are: ELISA, enzyme-linked immunosorbent assay;
PBS, phosphate-buffered saline; PBS-T, PBS-Tween 20 buffer; ALC,
anterior lens capsule; GBM, glomerular basement membrane; NC-I,
non-collagenous domain at the carboxyl terminus of type IV collagen;
7-S, collagenous domain at the amino terminus of type IV collagen.
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monomeric (Mr 28,000) and dimeric (M 56,000) components of
NC-I and to some degree at the trimeric (Mr 84,000) compo-
nent. The nature and location of the epitope which reacts more
strongly with sera from patients with GP has been investigated
by Saus et al [14], Gunwar et al [12], and Morrison, Germino
and Reeders [15]. Their findings suggest that the epitope is
located in the NC-i domain of the a3(IV) chain of basement
membrane coliagen and involves a peptide sequence comprising
amino acids 198 to 233. Fractionation of the bacterial collage-
nase digest of GBM or ALC yields fractions in which either the
NC-i or the 7-S region of the collagen type IV predominates.
Earlier studies from our laboratory indicated that, although sera
of the majority of patients with anti-GBM antibodies studied
reacted with the NC-i domain, a small number reacted with the
7-S domain as well [9], suggesting that some heterogeneity of
antibodies among OP patients may be present. Using the
enzyme-linked immunosorbent assay (ELISA), we demon-
strated various degrees of reactivity between epitopes on type
IV collagen from ALC and human anti-GBM antibodies [9].
Historically, ALC has provided an abundant source of base-
ment membrane free of contaminating interstitial connective
tissue components. To relate the reactivity of the anti-GBM
antibody radioimmunoassay with antigenicity of known sub-
units of GBM, we used coilagenase-resistant fragments of
bovine ALC to inhibit the reaction of GBM subunits with
patients' sera. Initiai studies in our laboratory had demon-
strated that a gel filtration fraction of solubilized bovine ALC
that contained the NC-i domain of type IV collagen was most
efficient in interfering with the anti-human GBM radioimmuno-
assay reaction (unpublished data). In the current study, we
report on the comparative reactivity of human anti-GBM anti-
bodies with (a) a fraction of collagenase solubilized human
GBM, purified by immunoaffinity chromatography, and with (b)
bovine and human ALC fractions corresponding to the NC-i
and 7-S domains of type IV collagen. The data show that sera
from patients with GP react by immunoblot and ELISA pre-
dominantly with the NC-i domain of bovine type IV collagen
from ALC. There were four patients whose sera reacted with
both the NC-i and 7-S domains, but more strongly with the
latter. The serum of one patient reacted only with the 7-S
domain. It is suggested that ALC from heterologous species can
be used as a source of antigenic components capable of reacting
with human GBM autoantibodies. The data also indicate that
there may be heterogeneity in the nature of autoantibodies
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reacting with type IV collagen epitopes in sera of patients with
GP.
Methods
Reagents
Human sera used in this study were obtained from patients
with glomernephritis or OP at a time when their antibody titers
against GBM were high and again when the titers were low or
absent as measured by the radioimmunoassay of Wilson [4].
Control sera were obtained from healthy adults and from
patients with rheumatoid arthritis, lung cancer and membra-
nous glomerulonephritis. Normal rabbit serum was obtained
from Cappel Laboratories, Malvern, Pennsylvania, USA (5012-
1380),
Rabbit antisera against the NC-i domain of BM collagen
(type IV)
The NC-i domain was prepared from bovine ALC by digest-
ing with bacterial coilagenase as described below. Antisera
against the NC-i domain were prepared in rabbits by injecting
100 g subcutaneously every other week for 11 weeks. The
immunogen was emulsified with an equal volume (1 ml) of
complete Freund's adjuvant. The rabbits were bled prior to
inoculation and bled out 1.5 weeks after the last injection [16].
Preparation of antigens
BM collagen (type IV). Native undegraded type IV collagen
was extracted from bovine ALC with 0.5 M acetic acid, and
purified on a DEAE-cellulose column as described by Brinker
et al [161. Rotary shadowing electron microscopy revealed
procoilagen-like molecules having a helical domain, a carboxyl
terminal, globular domain, and tetramers of such molecules
overlapping at their amino termini to form the 7-S domain [16].
Bovine and human GBM. GBM was prepared from bovine
and human kidneys. Bovine kidneys were obtained from the
local abattoire, Human kidneys were obtained from cadavers of
individuals who died without known renal disease. For the
preparation of GBM, renal cortices were isolated and processed
as described by Freytag, Ohno and Hudson [17].
Bacterial collagenase-resistant fractions of BM collagen.
The insoluble ALC that remained after extraction with 0.5 M
acetic acid or intact GBM were subjected to bacterial collage-
nase digestion [18]. Five hundred mg of lyophilized tissue was
suspended in 18 ml of 0.1 NI Tris-0.4 M NaCl, pH 7.4 buffer
containing protease inhibitors (N-ethylmaleimide, 3 mM;
PMSF, 1 mM) and CaCl2, 6 m. Bacterial collagenase (CLSPA-
Worthington Biochemicals, Freehold, New Jersey, USA) was
added at an enzyme/protein ratio of 1: 100, and the digestion
was allowed to proceed at 37°C for 20 hours. At the end of this
period, 1 ml of 100 mi EDTA was added, and the solubilized
protein was separated by centrifugation at 18,000 g for one hour
at 4°C. The supernatant was dialyzed exhaustively against
distilled water at 4°C and lyophilized. For gel filtration, 40 mg of
the lyophilized digest was dissolved overnight at 4°C in a 2 ml
solution of 1 M CaCl2 containing 50 mrvi Tris, pH 8.5, and 40 p.g
pepstatin (P-4265; Sigma Chemical Co., St. Louis, Missouri,
USA). The solution was warmed for 30 minutes at 45°C, and
then centrifuged at 18,000 g for 30 minutes at 22°C. The pellet
was discarded and the supernatant was placed on a 6% agarose
A-S m column (1.6 cm x 145 cm). Proteins were eluted with a
buffer containing 1 M CaCl2, 50 mii Tris-HCI, pH 7.5, at room
temperature at a flow rate of 14.8 ml/hr (Fig. 1) [191. The
fractions were dialyzed at 4°C against water and lyophilized.
Radioimmunoassay. Anti-GBM antibodies were detected us-
ing a double antibody radioimmunoassay which employs an
immunopurified fraction of collagenase solubilized human GBM
as an antigen. The immunoafilnity column was prepared with a
high-titer human anti-GBM antibody. Radiolabeled human IgG
was included to assess the degree of immunoglobulin precipi-
tation, and Na22 was included as an entrapment control. The
assay procedure and calculations are as described by Wilson
[4].
ELISA. Antibodies against type IV collagen and its fractions,
in patients with anti-GBM antibodies, were detected by ELISA.
The assay was performed essentially according to previously
described methods [16]. Native type IV collagen was coated in
Voller's buffer (0.15 M Na2CO3, 0.35 M NaHCO3, 0.02% NaN3)
at a concentration of 600 ng/well. The noncollagenous NC-i
domain of type IV collagen (Fig. 1, peak V) was coated at 1200
ng/well and the 7-S domain (Fig. 1. Peak III) was coated at 300
ng/well.
Polyacrylamide gel elect rophoresis (SDS-PAGE). SDS-
PAGE was performed on 5% or 9% polyacrylamide gels as
described by Laemmli [20].
Immunoblot. To further confirm the presence of antibodies to
type IV collagen and its NC-i and 7-S domains in the sera of
patients with anti-GBM antibodies, immunoblots were per-
formed as described previously [18].
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Fig. 1. Gel filtration of bacterial collagenase digest of anterior lens
capsule ('ALc on a 6% agrose A-5m column. Proteins were eluted with
a buffer containing I M CaCI2 in 50 mM Tris-HCI, pH 7.5. Peak I is the
void volume.
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Table 1. Amino acid and sugar compositions of ALC type IV
collagen and its collagenase-resistant fractions
ALC type
collagen
Collagena
Peak III
se digest
Peak V
Amino acida
Cysteic acid
3-Hydroxyproline 12.08 4.83 —
Methionine sulfoxide — 2.26 1.70
Hydroxyproline 82.55 96.28 Trace
Aspartic 40.51 39.32 59.73
Threonine 31.78 35.04 64.80
Serine 51.85 32.50 87.30
Glutamic 105.42 89.03 93.33
Proline 67.34 66.96 76.45
Glycine 263.97 316.24 100.54
Alanine 44.38 25.76 94.57
Cystine (reduced) 9.48 32.08 34.36
Valine 30.72 50.04 53.25
Methionine 13.69 5.08 15.45
Isoleucine 28.93 27.86 45.04
Leucine 56,15 42.66 73.20
Tyrosine 17.30 17.35 36.63
Phenylalanine 33.93 17.76 43.28
Hydroxylysine 35.27 41.41 4.48
Lysine 21.16 11.13 30.24
Histidine 15.48 12.24 36.14
Arginine 38.02 41.09 57.10
Sugars pg/mg protein
Mannose 6.84 34.07 1.85
Fucose 1.46 11.093 1.66
Galactose 30.77 44.40 2.57
Glucose 33.90 36.37 2.51
Fractions were isolated after bacterial collagenase digestion of ALC
and gel filtration.
a Residues per thousand
Immunodetection was performed using a protocol from Vec-
tor Laboratories (Burlingame, California, USA). In the case of
type IV collagen, a nitrocellulose membrane was incubated
with each of the following: rabbit anti-type IV collagen anti-
serum, at a dilution of 1: 100; normal whole rabbit serum, at a
dilution of 1: 100; anti-GBM antibody positive serum, at a
dilution of 1: 10; and control human serum, at a dilution of 1: 10.
Amino acid analysis. Amino acid analysis of whole type IV
collagen and its NC-l and 7-S domains was carried out as
described previously [19].
Rotary shadowing. Rotary shadowing electron microscopy
was performed on fractions of the collagenase digest of ALC
and GBM according to the method of Shotton, Burke and
Branton [21] as modified by Kuhn et al [22]. Photographs were
taken with a Hitachi model HU 1 iF electron microscope.
Magnification was calibrated with carbon replica grating (No.
1002, E.F. Fullam, Inc., Schenectady, New York, USA).
Results
Characterization of antigenic components of BM
BM collagen. Table I shows that the purified ALC extract
has a high 3- and 4-hydroxyproline content, whereas its alanine
content is low, consistent with previous analyses of type IV
collagen [16]. The equimolar amounts of glucose and galactose
as well as the low content of mannose and fucose further
confirm the nature of the material as type IV collagen.
Bacterial collagenase-resistant fractions of BM. The bacte-
rial collagenase-resistant fractions of ALC were resolved into
seven fractions on an agarose A-5m column (Fig. 1). Amino
acid analysis of peaks I and II revealed the noncollagenous
nature of the fractions, (data not shown). The analyses of peaks
III and V are shown in Table 1. Peak V had a noncollagenous
amino acid composition. Peak III was collagenous. The 4-hy-
droxyproline, hydroxylysine, and glycine content was much
higher than that seen in the intact type IV collagen, whereas the
alanine content was significantly lower. The cysteine content
was high, indicative of high disulfide cross linking within the 7-S
domain. The carbohydrate content was characterized by a
higher amount of galactose and a significantly higher content of
mannose and fucose, suggesting the presence of mannose
containing heteropolysaccharides.
Figure 2A shows a rotary shadowing electron micrograph of
the material eluting in peak V; it is composed of globular
domains characteristic of the NC-i domain. Globular compo-
nents were the only structures noted in peak V. Peak III was
composed entirely of rectangular pieces characteristic of the
7-S domain of type IV collagen (Fig. 2B). Similar results were
obtained with peaks V and III from the collagenase digest of
bovine and human GBM (data not shown).
The bacterial collagenase-resistant fractions which were
eluted on agarose A-Sm were further characterized by SDS-
PAGE (data not shown). Under reduced conditions peak V
contained peptides that migrated with an M = 28,000 and
56,000 suggesting a monomer-dimer relationship. Evidence for
a trimer with a Mr = 84,000 was suggested by a slow moving
band in peak V. Peak III which was composed of the 7-S
domain contained peptides migrating with an Mr between
52,000 and greater than 100,000.
Immunologic studies of BM components
Type IV collagen. The native type IV collagen was tested by
ELISA against sera from patients with GP. Figure 3 shows a
high degree of reactivity with four patient sera at dilutions
ranging from 1:20 to 1:160.
Collagenase resistant fractions of type IV collagen. When
the collagenase resistant fractions of ALC were tested by
ELISA against the anti-GBM positive sera, high reactivities
were noted with dilutions as high as 1:320. Figure 4 shows the
ELISA reaction of peak V which contains the NC-l domain. It
reacted strongly with the same two sera (numbers 1 and 7) that
had the highest reactivity with intact type IV collagen (Fig. 3).
Peak III (Fig. 5), which contains the 7-S domain, reacted
strongly against four anti-GBM antibody positive sera at a
dilution of 1:40, but only sera 1 and 7 gave strong reactions at
dilutions of 1: 160.
An attempt was made to correlate the reactivity of sera from
GP patients with the immunopurified human GBM collagenase
digest, as measured by the radioimmunoassay of Wilson [4],
and with peak V from bovine ALC as measured by ELISA.
Sera from the same patients were taken during the time of
anti-GBM antibody production and after the anti-GBM anti-
body was no longer detectable by the radioimmunoassay (less
than 1% binding).
Figure 6A shows that when the sera had no binding (solid
circles) by the anti-GBM antibody radioimmunoassay there was
little or no reactivity with peak V by ELISA. Only when the
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Fig. 2. Electron microscopic i'izualization of material fro,n peaks V (A) and III (B) of the gel filtration shown in Figure 1. Note the globular
particles (NC-i domain) in A and the rectangular particles (7-S domain) in B. Bar = 100 nM.
binding by radioimmunoassay rose above 15% was there a
similar increase in the reactivity to peak V by ELISA reaching
2 to 2.3 O.D. units. This indicated a positive although less
sensitive correlation with the presence of anti-GBM antibody
using the heterologous basement membrane antigen. The reac-
tivity of the sera from patients with cancer, with rheumatoid
arthritis, with membranous glomerulopathy, and from normal
individuals was low to absent with both methods of assay.
A similar correlation was attempted with peak III which
contains the 7-S domain of ALC type IV collagen. A few
anti-GBM antibody positive sera showing a high percent of
binding to the human GBM collagenase digest by radioimmu-
noassay also demonstrated a high reactivity to this fraction by
ELISA. Some GP patient sera that were negative by the
radioimmunoassay were also non-reactive by ELISA, whereas,
others showed moderate reactivity with peak III (Fig. 6B). On
20 40 80 160
Serum dilution
Fig. 3. An ELISA study with type IV collagen isolated from ALC.
Antigen at 600 nglwell. The reactivity of sera from four patients [(x—x)
#1, (—) #2, ( •) #4, (O—O) #71 with anti-GBM antibod-
ies and from one normal (S S N.S.) is shown.
the other hand, some UP sera which demonstrated a high
percent of binding to the human GBM collagenase digest by
radioimmunoassay showed low reactivities with the 7-S domain
by ELISA. Sera from two patients with rheumatoid arthritis,
from four with cancer, from one with membranous glomerul-
opathy and from three normal individuals reacted with peak III
by ELISA but had a negative reaction by the radioimmunoas-
say. These data indicate that patients with a variety of disor-
ders, including GP, may produce antibodies against more than
one domain of type IV collagen; however, the specificity of
reaction in GP is higher with peak V (NC-i domain).
Immunobiot analyses
Sera from patients anti-GBM antibodies were tested by
immunoblot against peaks III and V as well as against the
unfractionated bacterial collagenase digest of bovine ALC and
of bovine and human GBM.
Figure 7 shows the reaction of two anti-GBM antibody
positive sera (patients #3 and 1, respectively) in panels A and
B. Lane 1 in panel A depicts the reaction of one patient's serum
with the whole unfractionated collagenase digest of ALC and
lane 2, the reaction with peak V (NC-i domain) of the fraction-
ated collagenase digest, (electrophoresis carried out under
non-reducing conditions). Lane 3 shows the reactivity of the GP
serum with the same peak V and lane 4 with peak III (7-S
domain) under reducing conditions. Although both peaks are
reactive, the reaction is markedly diminished under reducing
conditions. Panel B shows the reactivity of another anti-GBM
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Fig. 4. An ELISA study with peak V (NC-I domain) of the collagenase
digest of ALC fractionated on agarose A-5m (Fig. 1). The reactivity of
sera from two patients [(x—x) #1, (O—O) #71 with anti-GBM
antibodies and from one normal (5 5) is shown. Antigen at i200
ng/well.
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Fig. 5. An ELISA study with peak III (7-S domain) of the collagenase
digest of ALC fractionated on agarose A-5m (Fig. 1). The reactivity of
sera from four patients (x—x) #1, (L—) #2, ( •) #4,(O—O) #7] with antiGBM antibodies and from one normal (S 5)
is shown. Antigen at 300 ng/well.
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Fig. 6. Reaction of GP sera with the NC-i
(A) and 7-S domains (B). Sera from patients
during antibody production and after the
antibody was no longer detectable (less than
1% binding) by radioimmunoassay are shown
as solid circles. The open squares represent
serum from patients with cancer. The solid
triangles are sera from patients with
rheumatoid arthritis. The open hexagons are2.5 sera from patients with membranous
glomerulopathy and the closed squares are
sera from normal individuals.
digests, comigrating with fractions from peak III reacts with the
GP serum, differences in reactivity between peaks III and V are
again noted. Panel B shows the reaction of the same fractions
(lanes in B are mirror image of lanes in A) with a normal serum.
Discussion
Initial studies by Wieslander et al [5, 6] and by Butkowski et
al [7], suggested that the GP antigen of the GBM localized in the
non-collagenous regions of type IV collagen. They further
suggested that the GP epitope was contained in a non-collage-
nous polypeptide fragment, released by digestion with bacterial
collagenase, which exists as a monomer (Mr = 26,000) and a
dimer (M = 50,000). These subunits were designated M2 and
D2, respectively. Later studies by Butkowski et al [8] and Saus
et al [14] suggested that M2 and D2 are not components of the
al or a2 chains of the type IV collagen but rather arise from a
novel basement membrane collagen chain. A cDNA clone
representing the a3(IV) chain of basement membrane collagen
has been reported recently [15] and evidence has been pre-
sented that the NC- 1 domain of this chain contains an epitope
that reacts with GP sera [13].
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antibody positive serum with the same fractions as in panel A.
Note the differences in the degree of reactivity between the sera
in panels A and B. Note also the strong reaction with peak III
(7-S domain) even under reduced conditions (panel B, lane 4).
Lane 1 in Panel B shows reactivity with high molecular weight
component only, suggesting reaction with the 7-S domain. No
reaction was noted with a normal serum (panel C). Panel D
shows an immunoblot with a purified sample of peak V and a
specific rabbit antiserum.
Figure 8 shows the comparative reactivity of an anti-GBM
antibody positive serum with material from peaks III and V of
the collagenase digest of bovine and human basement mem-
branes. In panel A there is a strong reaction with peak V from
bovine GBM and ALC (lanes 1 and 4, respectively) as well as
with whole collagenase digest from human GBM (lane 2) and
from bovine ALC (lane 3). The reactivity of peak III (under
reducing conditions) from bovine ALC and GBM is shown in
lanes 5 and 6, respectively. Lanes 7 and 8 show respectively the
reactivity of unfractionated collagenase digest from bovine
ALC and human GBM (under reducing conditions). Although
material from both the human and bovine whole collagenase
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Fig. 7. Electroimmunoblot of sera from patients (#1 and #3 respectively) with anti-GBM antibodies (A and B) and from a normal (C). Lanes 1
and 2 in panels A, B and C under non-reduced conditions. Lanes 3 and 4 in all panels, and panel D under reduced conditions. Lanes 1 in panels
A and B, unfractionated collagenase digest of ALC. Lanes 2 and 3 in panels A and B, peak V (NC-i domain) from Figure 1. Lanes 4 in panels A
and B, peak III (7-S domain) from Figure 1. Panel D shows the reactivity of Peak V with an antiserum against it prepared in rabbits.
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Fig. 8. Electroimmunoblot of a serum from a patient with anti-GBM antibodies (A) and from a normal (B). Lanes 1—4 in both panels are under
non-reduced conditions. Lanes 5—8 in both panels are under reduced conditions. Lanes 1 and 4, material from peak V of bovine GBM and bovine
ALC, respectively. Lanes 2 and 3, material from whole collagenase digest of human GBM and bovine ALC. Lanes 5 and 6, material from peak
III (7-S domain) of bovine ALC and bovine GBM, respectively. Lanes 7 and 8, material from whole collagenase digest of bovine ALC and human
GBM, respectively.
The data presented here demonstrate that patients with lagenous and non-collagenous domains of the basement mem-
anti-GBM antibodies associated with Goodpasture syndrome or brane collagen (type IV). Unpublished data from our laboratory
glomerulonephritis alone carry antibodies directed against col- demonstrate that a number of the anti-GBM antibody positive
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sera also reacted by ELISA with mouse and human laminin. A
similar reaction with lamjnin was noted with sera from patients
with poststreptococcal glomeruionephritis [18]. Anti-GBM an-
tibodies are capable of reacting not only with the human
basement membrane components but with bovine as well. The
NC-i and 7-S domains of type IV collagen are capable of
reacting with sera containing anti-GBM antibodies from pa-
tients with GP. The reactivity of these sera with the 7-S domain
cannot be due to contamination of the latter by material from
the NC-i domain, since Peak V under reduced conditions
shows little reactivity with the GP serum, whereas peak III,
representing the 7-S domain, reacts quite strongly (Fig. 7B).
Reactivity of the anti-GBM antibody positive sera with the
intact type IV molecule and with both the NC-i and 7-S
domains was demonstrated by ELISA (Figs. 3 to 5) as well as
by immunobiot (Figs. 7 and 8). However, when a comparison
was attempted between the reactivity of these domains mea-
sured by ELISA and by a specific radioimmunoassay for the
human GBM antigen, the specificity of the reaction was greater
for the NC-i domain than for the 7-S domain. Although four
anti-GBM antibody positive sera showed a high reactivity with
the 7-S domain by ELISA, the majority of anti-GBM antibody
positive sera demonstrated a low reactivity when the reactivity
against the NC-i domain was high by radioimmunoassay.
Furthermore, sera from patients with disorders, such as rheu-
matoid arthritis, cancer or membranous glomeruionephritis
reacted with the 7-S domain by ELISA but showed a negative
reaction by the radioimmunoassay of Wilson [4] (Fig. 6 A and
B).
Antibodies against other basement membrane components,
such as laminin [181 or heparan sulfate proteoglycan [23], may
arise as a secondary non-specific response or it is possible that
more than one epitope is responsible in the production of
nephritogenic antibodies. In this respect, it can be stated that a
bacterial or viral infection leads to a tissue injury, which in turn
may damage basement membranes resulting in the production
of antibodies directed against a number of tissue components.
In patients with anti-GBM antibody disease, through some
unknown mechanism, antibodies are produced against a minor
component in vascular basement membranes, a process that
can lead to severe tissue damage. The rarity of this syndrome
suggests: (1) that the antigenic epitope(s) or their accessibility
may vary, possibly as a result of mutation in the structural
gene(s) responsible for the synthesis of basement membrane
collagen; (2) another collagen molecule kept at very low
amounts in normal basement membranes may be produced in
higher yields in patients destined to develop GP 114], and (3)
that GP patients who develop anti-GBM antibodies may have
an abnormality in their immune system which allows specific
antibody producing cells to produce autoantibodies.
To pinpoint more precisely the epitopes that give rise to
anti-GBM antibodies in humans, we must employ additional
approaches [24]. One approach may come from the application
of information obtained through recombinant DNA studies of
the genes responsible for the expression of proteins in basement
membranes. In a number of laboratories cDNA clones have
been isolated for the NC-i domain of the human al (IV) and a2
(IV) procollagen chains [25—3 1] and more recently for the
a5(IV), s3(IV) [15], and a4(IV) chain [321.
Recently, we have identified antigenic determinants in the
NC-i domain of type IV collagen that are reactive with anti-
GBM antibody positive sera by using synthetic peptides corre-
sponding to segments of the human al(IV), a2(IV) and a3(IV)
procoliagen chains [33 and 34, in this issue].
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